Results 51 to 60 of about 350,788 (241)

The impact of loco-regional recurrences on metastatic progression in early-stage breast cancer: a multistate model [PDF]

, 2009
To study whether the effects of prognostic factors associated with the occurrence of distant metastases (DM) at primary diagnosis change after the incidence of loco-regional recurrences (LRR) among women treated for invasive stage I or II breast cancer ...
A Fourquet, AC Voogd, B Fisher, B Fisher, B Fisher, C Vrieling, C. J. van de Velde, D Cowen, E Touboul, Early Breast Cancer Trialists’ Collaborative Group, G Coulombe, G. H. de Bock, H Bartelink, H Kemperman, H Putter, H. Bartelink, H. Putter, HM Nielsen, I Soerjomataram, J Dongen Van, J Engel, J Hage Van der, J Hage Van der, J Ragaz, J. A. van der Hage, J. Bonnema, JA Dongen Van, JA Dongen Van, JG Nes Van, L Livi, M Clarke, M Leest Van der, M Sangen Van der, MA Bollet, N Kroman, P Broet, PC Clahsen, PH Elkhuizen, PH Elkhuizen, R Arriagada, R Arriagada, RS Punglia, U Veronesi, WS Halsted   +43 more
core   +3 more sources

The subcellular distribution of phosphorylated Y‐box‐binding protein‐1 at S102 in colorectal cancer patients, stratified by KRAS mutational status and clinicopathological features

Molecular Oncology, EarlyView.
This study identifies nuclear YB‐1 S102 phosphorylation as a marker associated with KRAS and FBXW7 mutations in colorectal cancer. Mutated KRAS correlates specifically with nuclear, not cytoplasmic, S102 YB‐1. These findings provide the first ex vivo evidence of this link in CRC and suggest future studies should assess the prognostic and therapeutic ...
Konstanze Lettau, Stephan Forchhammer, Birgit Fehrenbacher, Lejla Mahmutovic, Marcus Scharpf, Gunnar Blumenstock, Martin Schaller, Irina Bonzheim, Shayan Khozooei, Mahmoud Toulany   +9 more
wiley   +1 more source

Downregulation of O‐GlcNAcylation enhances etoposide‐induced p53‐mediated apoptosis in HepG2 human liver cancer cells

FEBS Open Bio, EarlyView.
Etoposide, a topoisomerase II inhibitor, reduces O‐GlcNAcylation in HepG2 liver cancer cells. Further inhibition of O‐GlcNAc transferase by OSMI‐1 enhanced etoposide‐induced apoptosis, lowering the IC50 for viability and increasing the EC50 for cytotoxicity.
Jaehoon Lee, Gi‐Bang Koo, Jihye Park, Byung‐Cheol Han, Mijin Kwon, Seung‐Ho Lee   +5 more
wiley   +1 more source

Male patients commencing FOLFOX / FOLFIRI chemotherapy in 2014, descriptive statistics [PDF]

, 2016
Background: Metastatic colorectal cancer is an incurable illness; however the advent of chemotherapy has significantly improved survival and symptom control.
Alarayedh, Ameer A., Almuqamam, Mohamed A.   +1 more
core  

Trastuzumab (Herceptin (R)): Monoclonal antibody in the treatment of HER2/neu-overexpressing breast cancer in the metastatic and (neo)adjuvant situation [PDF]

, 2006
Trastuzumab (Herceptin (R)) is a humanized monoclonal antibody that specifically targets HER2/neu (human epidermal growth factor receptor-2) breast cancer cells, which are overexpressed in about 25-30% of breast carcinomas.
Bauerfeind, Ingo, Ditsch, Nina, Friese, Klaus, Kahlert, Steffen, Kümper, Carolin, Lenhard, Miriam, Rückert, Sandra, Untch, Michael   +7 more
core   +2 more sources

Long non‐coding RNAs as therapeutic targets in head and neck squamous cell carcinoma and clinical application

FEBS Open Bio, EarlyView.
Long non‐coding RNAs (lncRNAs) occupy an abundant fraction of the eukaryotic transcriptome and an emerging area in cancer research. Regulation by lncRNAs is based on their subcellular localization in HNSCC. This cartoon shows the various functions of lncRNAs in HNSCC discussed in this review.
Ellen T. Tran, Ruchi A. Patel, Amogh Chariyamane, Ratna B. Ray   +3 more
wiley   +1 more source

Evaluating predictive pharmacogenetic signatures of adverse events in colorectal cancer patients treated with fluoropyrimidines [PDF]

, 2013
The potential clinical utility of genetic markers associated with response to fluoropyrimidine treatment in colorectal cancer patients remains controversial despite extensive study.
A Fariña-Sarasqueta, A Loganayagam, A Ruzzo, A Ruzzo, A Yawata, A Zaniboni, Andreas-Claudius Hoffmann, Ann Barrett, B Glimelius, BA Jennings, Barbara A. Jennings, C Fernandez-Rozadilla, C Zhang, CE de Bock, CF Thorn, D Caronia, Daniel Epurescu, DB Longley, E Hitre, E Van Cutsem, G Willis, Gavin S. Chu, Gavin Willis, H Gellekink, H Taflin, I Weisberg, J Cassidy, Jane Skinner, K Derwinger, K Kawakami, K Kawakami, L Peter, L Sharp, M Boisdron-Celle, M Gusella, M Scartozzi, M Schwab, M Vignoli, ME Fernández-Contreras, Melanie Keane, MJ Deenen, MS Braun, MV Mandola, MV Mandola, MV Mandola, N Horie, P Frosst, R Pullmann Jr., RA Goodwin, Richard Turner, S Afzal, S Afzal, S Kaneda, T André, TV Perneger, V Sulzyc-Bielicka, W Ichikawa, W Scheithauer, WG Johnson, Yoon K. Loke   +59 more
core   +3 more sources

Understanding and Overcoming Immunotherapy Resistance in Skin Cancer: Mechanisms and Strategies

Aging and Cancer, EarlyView.
This narrative review explores the mechanisms driving immunotherapy resistance in skin cancer, including tumor microenvironment factors, genetic mutations, and immune evasion strategies. It highlights potential strategies to overcome resistance, offering insights for improving therapeutic outcomes and guiding future research in personalized ...
Shreya Singh Beniwal, Abhimanyu Chiraparambil Radhakrishnan, Ayanchetty Haripraba, Saif Syed, Gajawada Pragna, Ayush Dwivedi, Akash Rawat, Daniela Castro Calderón, Martin Cevallos‐Cueva   +8 more
wiley   +1 more source

Adjuvant chemotherapy with or without bevacizumab in patients with resected non-small-cell lung cancer (E1505): an open-label, multicentre, randomised, phase 3 trial. [PDF]

, 2017
BackgroundAdjuvant chemotherapy for resected early-stage non-small-cell lung cancer (NSCLC) provides a modest survival benefit. Bevacizumab, a monoclonal antibody directed against VEGF, improves outcomes when added to platinum-based chemotherapy in ...
Adjei, Alex A, Aisner, Seena C, Butts, Charles, Chapman, Andrew E, Dahlberg, Suzanne E, ECOG-ACRIN, Evans, Tracey, Gandara, David R, Graziano, Stephen L, Horn, Leora, Kasbari, Samer S, Keller, Steven M, Leighl, Natasha B, McDermott, Sean R, Patel, Jyoti D, Perez-Soler, Roman, Ramalingam, Suresh S, Rothman, Jan M, Sborov, Mark D, Schiller, Joan H, Shafqat, Atif, Tester, William J, Traynor, Anne M, Wakelee, Heather A   +23 more
core   +1 more source

Novel CT radiomics models for the postoperative prediction of early recurrence of resectable pancreatic adenocarcinoma: A single‐center retrospective study in China

Journal of Applied Clinical Medical Physics, EarlyView.
Abstract Purpose To assess the predictive capability of CT radiomics features for early recurrence (ER) of pancreatic ductal adenocarcinoma (PDAC). Methods Postoperative PDAC patients were retrospectively selected, all of whom had undergone preoperative CT imaging and surgery. Both patients with resectable or borderline‐resectable pancreatic cancer met
Xinze Du, Yongsu Ma, Kexin Wang, Xiejian Zhong, Jianxin Wang, Xiaodong Tian, Xiaoying Wang, Yinmo Yang   +7 more
wiley   +1 more source